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Translational research as a tópos
The Merriam-Webster dictionary reports the first use of “Translatio-
nal Research” as early as 1986 and the definition given for this term 
was: “medical research that is concerned with facilitating the practical 
application of scientific discoveries to the development and implemen-
tation of new ways to prevent, diagnose, and treat disease, called also 
translational medicine” [1]. The adjective “translational” stems from 
Classical Latin “translatio”, then probably Middle French ”translation”, 
to reach Middle English “translacioun”. The idea is to make a transfer 
from one idiom to another, yet keeping the intimate significance and 
sense, which is common to language translation methods. It properly 
stresses the relation to the transfer of scientific knowledge into prac-
tical applications. It is obvious how, in less than 30 years, translatio-
nal research has pervaded all Science domains and how large is the 
interest of scientists and lay people for this subject.
Medicine in general was particularly seduced by the translational 
concept, probably for its peculiar applied scopes. Cardiology was 
not an exception. Just to quote few among several examples: a) 
the International Society for Cardiovascular Translational Research 
[www.isctr.org] was formed in 2007 with the mission to provide an 
environment for collaboration and guidance among basic and clinical 
scientists, regulatory authorities and the medical industry to expedite 
scientific discoveries into clinical applications, disseminate the science 
among the scientific community and promote research, development 
of guidelines for training and certification in Translational Research, 
influence health care policy, educate the public, and improve the 
well being of patients. Regular symposia have now reached the 7th 
edition and the Society is expanding; b) a Journal of Cardiovascu-
lar Translational Research [ISSN: 1937-5387 (Print); 1937-5395 (On-
line)] was published by Springer starting 2008; as of 2013 it has a 
fair Impact Factor of 2.691 with regular issues every other month, 
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monthly from October 2014; c) the newly selec-
ted Editor-in-Chief of the Journal of the American 
College of Cardiology has implemented a special, 
blue highlighted, Perspectives window on publis-
hed articles, whereby the Translational Outlook is 
given, which stresses the importance of what is 
presented and why it might deserve further appli-
cability. For example, Martínez-Legazpi et al. con-
cluded that using the intraventricular vortex ring, 
the normal ventricle in sinus rhythm enters 10% to 
15% of its filling volume at no metabolic or pres-
sure cost; consequently enhanced vortex function 
reduces chamber operative stiffness in conditions 
of eccentrically remodeled ventricles, such as non 
ischemic dilated cardiomyopathy whereas reduc-
tion of vortex-mediated filling is a mechanism of 
diastolic dysfunction in severe concentric remo-
deling diseases, such as hypertrophic cardiomyo-
pathy [2]. The Journal’s translational outlook was 
that “Impaired vortex flow can be used to evaluate 
interventions and devices that influence diastolic in-
traventricular flow and global diastolic function in 
patients with various forms of acute and chronic 
cardiac disease.” [2].
The director of the National Institute of Neurolo-
gic Diseases and Stroke (NINDS) posted on March 
2014 a blog on secular changes in the nature of 
research supported by the Institute. Noting that offi-
cial definitions of basic and applied research were 
not helpful, the NINDS defined basic research as 
“an understanding of the structure and function 
of the nervous system,” whereas applied research 
was “aimed at developing and testing diagnostics, 
therapeutic agents, or preventive interventions.” 
They subclassified basic research into “basic/basic,” 
which “focused on understanding the normal ner-
vous system,” and “basic/disease-focused,” which 
“focused on understanding disease mechanisms.” 
The NINDS found a marked decline, from 1997 to 
2012, in support for basic research (from 87% to 
71% of expenditures), accompanied by a marked in-
crease (from 13% to 29%) in applied research. What 
the NINDS subclassified as basic/basic research had 
the steepest decline in applications and financial 
support (from 52% to 27%): they commented that 
possibly the applicants themselves might have just 
thought that the NINDS had simply low interest in 
that type of research. Recognizing the need to play 
a bigger role in bridging the gap between the disco-
very of a potential therapy and its development and 
clinical testing, the NINDS has just launched (August 
13, 2014) 3 carefully crafted funding programs, each 
tailored to specific treatment modalities and 2 of 
these, CREATE (Cooperative Research to Enable and 
Advance Translational Enterprises) Bio, and CREATE 
Devices are fundamentally Translational Research 
programs to offer support for preclinical develop-
ment and potentially small clinical trials and allow 
researchers in academia and small companies the 
opportunity to play a more active part in translating 
their basic neuroscience discoveries into treatments 
[3].
In the launching Editorial of the new Elsevier 
Journal EBioMedicine in November 2014 “as a 
centralized forum where clinicians and scientists in 
both the clinic and the laboratory can communica-
te their observations, ideas, and research insights 
and work together to address outbreaks such as 
Ebola and other major biomedical health challen-
ges” Stacey and Le stated [4] that the new Jour-
nal is certainly translational but asked “how we 
define translational research?” They pointed out 
that: “Technology has become so powerful and so 
nimble that personalized whole-genome sequen-
cing is likely to be within our reach as a practical 
clinical tool. For example, clinicians may now use 
genomic screening to stratify cancer patients into 
groups that might benefit from targeted, gene-
specific treatments that are in turn derived from 
recent basic science advances in the underlying 
biology of those altered genes. Translational me-
dicine endeavors to bring basic researchers and 
clinicians together in a common space where great 
discoveries in the laboratory can be applied directly 
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and rapidly in the clinic. The field also depends on 
the input and feedback from those at the forefront 
of clinical care, their daily observations in the clinic 
being critical for both detecting the emergence of 
new public health concerns and communicating 
the progress of new treatment modalities.”. They 
nicely concluded that “Translational research is 
therefore inherently bidirectional and far reaching 
in its scope and applications.”.
Therefore, in some sparse way, the what trans-
lational means in Cardiology, whether it deserves 
attention, how might it be fostered by Scientific 
Societies or Public Grant Authorities has been ad-
dressed in recent interventions, all sharing the need 
of stimulating a closer relation between basic scien-
tists (from biology [3,4] to epidemiology [5]) and 
applied clinicians, also bidirectionally [4]. It is less 
clear for whom and why. When a short Perspecti-
ve paragraph is put in comment and highlight of 
a relatively complex and quite long manuscript [2] 
it is not always easy for a Reader to completely 
understand/translate the message and then apply 
the presented new evidence or concept to the daily 
care, finding the full significance of the translatio-
nal concept. The reverse should also be true: how 
could the over-occupied clinician devote time and 
attention to a conversation with a fundamentalist 
in order to ask questions that may be replied from 
the bench? It is therefore needed, as in beautiful 
translations for Literature or Poetry of different cul-
tures into our own, that experts in the two langua-
ges (and cultures) act as translators and in order 
to be effective some rules should be followed not 
limited to word by word transfer but entering sen-
se, tune and philosophy.
Translational research might be a Tópos (τόπος, in 
Greek ‘place’ from tópos koinós, common place), in 
Latin locus (from locus communis), referred in the 
context of classical Greek rhetoric to a standardised 
method of constructing or treating an argument1. 
Tópoi (the plural) can be used to invent arguments 
and also to conceptualize and formulate the single-
sentence declarative thesis. They were defined as 
“ways of probing one’s subject in order to find 
the means to develop that subject” [6]. There are 
4 Tópoi that are most useful to students and/or 
scholars: definition, analogy, consequence, and tes-
timony2. Teaching the Tópoi requires using exam-
ples and good examples are to be had by applying 
each topic to a definite subject and coming up with 
several thesis statements [6].
It is the purpose of the present Editorial to offer 
the Readership of the International Archives of 
Medicine the rationale of 2 most important Tópoi. 
Thus we explicitely address the “why” and the “to 
whom” we decided that a Translational Cardiology 
Section was appropriate to fill the gap between 
basic and clinical Science. To be pragmatic few se-
lected examples were chosen and we present the 
essential of what a manuscript should contain in 
1.  Aristotle divided Tópoi into “common” and “special” groups. In the common group could be found categories such as laws, witnesses, contracts, 
oaths, comparisons of similarity, difference, or degree, definitions of things, division of things (whole/parts, for instance), cause and effect, and other 
items that could be analyzed, researched or documented.
2.  Definition involves the creation of a thesis by taking a fact or an idea and explaining it by precisely identifying its nature; it always asks the ques-
tion “What is/was it?” Analogy is concerned with discovering resemblances or differences between two or more things proceeding from known to 
unknown; it is a useful tool for investigating comparisons and contrasts because it always asks the question “What is it like or unlike?” Consequence 
investigates phenomena costs to effect-to-cause pattern, best established through probabilities from patterns that have previously occurred. It always 
answers the question “What caused/causes/will cause it?” Testimony relies on appeals to an authority (such as an expert opinion, statistics, or the law) 
and it always answers the question “What does an authority say about it?” “Ultimately a thesis or an argument must say something about the real 
world.”
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order to serve under these flags. Our contribution 
is allocated under 2 items and it principally offers 
considerations starting from our own experience, 
which enabled our critique to be potentially less 
constrained.
It is almost a requirement for translational research 
that it should be inspired by the clinic. Translational 
research is often defined as “bench to bedside” but 
it is safe to state that the initial step is invariably 
taken from clinical observations. This is the phase 
when a particular clinical problem incites the resear-
chers to look into the basic science background and 
formulate “translational” hypotheses. Therefore, we 
“reversed” what is considered the “standard” pre-
sentation, with the clear-cut allusion to the need of 
being clinically driven, underpinning what we stron-
gly believe is the force and impact of translational 
research in Cardiology, namely to be derived from 
a clinical question and to aim at solving a clinical 
problem or adding to pathophysiological concepts 
or mechanisms new elements for prevention, diag-
nosis or treatment.
Translational research in 
Cardiology: from the bedside 
to the bench
In a recent study using 3 dimensional data obtai-
ned by Speckle Tracking Echocardiography (3DSTE) 
to detect semi-automated and homologous land-
marks clouds as proxies of left ventricular heart 
morphology, an extended Geometric Morphome-
trics toolkit distinguished between intra- and inter-
individual shape variations [7]: a special strategy 
compared the shape, orientation and size of car-
diac cycle’s morphological trajectories in time. The 
fundamental, physiologically-based assumption 
was that shapes of trajectories with inter-individual 
variation are expressions of left ventricular heart 
function when compared at electrophysiologically 
homologous times [7,8]. Using a special type of 
Riemannian Parallel Transport, called “linear shift” 
human left ventricular heart morphological chan-
ges in time were compared among 17 healthy 
subjects and 2 patients with volumetric overload 
due to Aortic Regurgitation (AR). Whereas the 2 
patients with AR were not differentiated in the sta-
tic shape analysis from the healthy subjects, they 
set apart significantly in the analyses of trajectory’s 
shape and orientation. In healthy subjects, the va-
riations due to inter-individual morphological diffe-
rences were not related to shape and orientation 
of morphological trajectories. Principal Component 
Analysis showed that volumetric contraction, tor-
sion and twist are differently distributed on diffe-
rent axes. Moreover, global shape change appea-
red to be more correlated with endocardial shape 
change than with the epicardial one. Finally, the to-
tal shape variation occurring among different sub-
jects was significantly larger than that observable 
across properly defined morphological trajectories 
[7]. This type of investigations was extended, more 
recently, to patients with hypertrophic cardiomyo-
pathy (HCM) with positive genotyping [9]. Figu-
re 1 illustrates how the analysis of morphological 
trajectories through time can unveil some patho-
physiological differences among heart diseases. A 
group of healthy subjects (n=48) is compared with 
a group of Hypertrophic Cardiomyopathy patients 
(HCM, n=24) and preliminarily with 2 patients 
affected by AR. This analysis detects significant 
differences in trajectories orientation in the PC1-
PC2 shape space. Orientation is defined by the 
vector connecting PC values at R-peak with those 
at the end-systolic volume time. The translational 
example here is represented by the potential to 
start from a clinically adopted diagnostic tool as 
3DSTE whereby morphometric parameters are ob-
tained after dedicated elaborations and then adapt 
mathematical, statistical and engineering (in case 
of principal strain lines [8]) tools to finally conclude 
that volume and pressure overloads have opposite 
consequences on those parameters. In return these 
efforts might eventually be used clinically if peculiar 
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conditions such as genotype positive but phenoty-
pe negative HCM individuals might so be disclosed 
as abnormal [10]. It is interesting that using com-
pletely different approaches, the vortex visualized 
from inside left ventricular wall [2] and morphome-
trics and principal strain lines evidenced from out-
side [7-10], both representing medical-engineering 
interactions, the conclusions are not dissimilar from 
the translational point of view, namely that im-
pairments represent or index peculiar pathological 
conditions and may thus be used diagnostically. As 
these methods are very subtle, it should now be 
essential to know whether they might be applied 
early enough to secure diagnostic elements when 
the situation is not still advanced as is the case by 
standard methods. Here only should a crown be 
on such research, which illustrates how important 
is time in translational research.
In the context of both acute and chronic ische-
mic heart disease, prolongation of the electrocar-
diographic (ECG) interval QTc was a predictor of 
sudden death due to life-threatening arrhythmias 
as ventricular fibrillation [11-13] which is known 
from a long time. When standard ECGs were per-
formed in patients intoxicated by glyphosate-based 
herbicide (GBH) [14] and among those intoxicated 
by Roundup [15], the most used herbicide in the 
world, at least 1 abnormal ECG was detected in 
80% of patients and both QTc prolongation and 
arrhythmias along with first degree atrio-ventri-
cular block were observed. However, the actual 
mechanistic effects were not explained as, unbelie-
vably, no investigations were performed in cardiac 
mammalian tissues principally based on the idea 
that GBH or Roundup are inert components when 
animals or humans are exposed acutely [15]. It was 
Figure 1:  By defining orientation as the vector connecting Principal Component (PC) values at R-peak 
with those at the end-systolic volume time, the starting point is common to all studied indivi-
duals: a) healthy subjects (n=48); b) Hypertrophic Cardiomyopathy (HCM, n=24) patients and c) 
Aortic Regurgitation (AR, n=2) patients. Significant differences in trajectories orientation in the 
PC1-PC2 shape space are seen in HCM versus AR patients. Healthy subjects (whose trajectory 
orientation line is not significant) stay in the middle.
.
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quite rational therefore to investigate in vitro rat 
and rabbit ventricular tissues by standard electro-
physiology to assess, for the first time, whether 
APD90 increase (the in vitro counterpart of QTc 
prolongation) might follow to short superfusion of 
Roundup, which was seen in conjunction with a 
high incidence of severe arrhythmias and of con-
duction blocks at the highest concentrations [16]: 
Figure 2 illustrates the rabbit case. Arrhythmias 
and conduction blocks may follow to significant 
INa and IK blocking properties [16], possibly rela-
ted to the cation chelator ability [17] of glyphosa-
te and to decreased 45Ca++ influx through L-type 
voltage-dependent Ca++-channels shown by both 
Roundup and glyphosate [18]. 
Although it will be critical to further study the va-
rious components of IK to assess which contributes 
the most, the translational aspects here were nicely 
shown and human risks after acute intoxication [14] 
were linked to animal ones [16] demonstrated by 
electrophysiological changes seen in mammalian 
ventricular myocardium, including conduction blocks 
and arrhythmias among GBH-mediated effects. The 
importance of the experimental investigations to 
elucidate the intoxication mechanisms by Roundup 
(and/or GBH in general) in humans is indeed very 
Figure 2.  Representative example of serious premature ventricular contractions occurring in rabbit ven-
tricular tissues in vitro after Roundup superfusion. As compared to baseline experiment, fre-
quent premature ventricular beats were seen after 30 min of Roundup 50 ppm superfusion 
(modified from [15]). Also note APD90 increase that in 6 experiments, from 131±2 (mean±SE) 
ms reached 153±9 ms (p<0.005) [16].
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high, since a large proportion among as many as 
25 million agricultural workers in the developing 
world suffers an episode of herbicide poisoning 
every year [16]. This research deserves top priority, 
ideally from independent Investigators, in order to 
confirm the findings and further define the role of 
IK. Furthermore, it represents an example of how 
clinically formulated questions may be addressed in 
the laboratory to develop a translational impact on 
future treatment.
Translational research in 
Cardiology: from the bench to 
the bedside
Two definite clinically-driven examples of basic re-
search are presented: firstly the research that has 
been performed around the use of left ventricular 
assist devices (LVADs) for the treatment of heart 
failure and that has exploded into new hypotheses 
and different directions of clinical research through 
a journey into basic research, and secondly the dis-
covery of the pace-maker current If and its inhibitor 
ivabradine and the subsequent highs and lows in 
the clinical applications. The very debated, expen-
sive, and so far yet to be proven effective, use of 
stem cells for regenerative purposes, is deliberately 
omitted from this analysis, as this deserves a sepa-
rate and more detailed account that will be covered 
extensively in future issues of the Journal.
LVADs have been developed in the last half cen-
tury in the quest for replacement of the injured 
heart with an artificial heart [19]. LVADs are me-
chanical pumps that are surgically implanted and 
can support the circulation when cardiac function 
is insufficient, while unloading the LV. Originally 
extracorporeal and short-term, they can now be 
implanted in the chest for long periods of time 
(months/years) and successfully used in patients 
with severe heart failure as a bridge-to-transplan-
tation and even as permanent treatment (destina-
tion therapy) [19]. Despite significant technical ad-
vances, LVAD use is significantly hindered by a very 
high incidence of serious complications and cost, 
and can affect quality of life, thus remaining as a 
palliative, not a curative option for most patients 
[20]. In early cases when explantation of the devi-
ces was required due to technical faults or compli-
cations, it was noticed that, after LVAD treatment, 
there was an obvious reduction in heart size and 
an improvement in myocardial performance [21]; 
this suggested the possibility that the dysfunctional 
spiral that leads to permanent remodeling and the 
clinical syndrome of heart failure can be reversed 
by unloading. This observation triggered a flurry of 
basic research to describe details and understand 
mechanisms, in a typical translational example, with 
the goal to feed back to the clinic and optimize this 
modality for heart failure treatment (“bridge-to-
recovery”) [22,23]. Two major platforms of “basic” 
research were developed. The first employs myo-
cardial biopsies from patients, leveraging from the 
unique set of circumstances where relatively large 
amounts of myocardium can be ethically obtained 
at two time points from the same LVAD patient: 
the first – LVAD core – at the time of the implan-
tation of the device in the LV and the second at 
the time of LVAD explantation during cardiac trans-
plantation. Moreover, to overcome problems due 
to small patient numbers, high variability and lack 
of normal myocardium in human studies, a number 
of animal models of chronic mechanical unloading 
and heart failure were developed [24]. A detailed 
account of these studies is outside the scope of this 
Editorial and can be found elsewhere [22,25] but 
the results were extraordinary: a large number of 
parameters tested, from the hypertrophic response 
to beta adrenergic signaling, from gene expres-
sion to metabolic pathways, were found to be nor-
malized or significantly improved after unloading 
(reverse remodeling). This demonstrated that the 
pathological substrate of heart failure, previously 
considered a set of irreversible degenerative chan-
ges, can in fact be reversed and that recovery from 
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heart failure is possible. The interaction between 
basic and clinical studies in this field did not stop 
there: the lack of a direct correlation between re-
verse alterations of the substrate and clinical re-
covery following LVAD treatment [26] (the latter 
remains low, with only 5-10% devices explanted) 
initiated another step in the translational journey 
to establish a causal relationship. That is, specific 
biological mechanisms linked to clinical recovery 
or linked to its failure were needed. One of these 
studies looked at a population of patients treated 
with a combination of VAD and pharmacological 
therapy and linked to a higher recovery success 
rate (Figure 3) [27]. It was found that an improve-
ment in sarcoplasmic reticulum (SR) calcium cycling 
of ventricular cardiomyocytes is associated with 
clinical recovery, while the reduction in cell size 
following LVAD was not important. This is clinically 
relevant and translational for two reasons: the first 
is that SR calcium regulation becomes an essential 
Figure 3.  Ventricular biopsies where taken at the time of LVAD implantation in patient with severe heart 
failure (HF – pre LVAD). Following treatment, some patients showed a marked regression of 
clinical HF parameters and the LVAD could be explanted without recurring to cardiac trans-
plantation. During surgery, ventricular samples were collected (clinical recovery- post LVAD). 
In other patients LVAD treatment did not result in clinical improvement and the patients un-
derwent cardiac transplantation during which ventricular samples were collected (HF – post 
LVAD). Myocytes were isolated from the 3 groups of biopsies and sarcoplasmic reticular (SR) 
calcium content was measured using microelectrode techniques. (* = p <0.05; ** = p <0.01; 
mito = mitochondrial). Modified from [27]. 
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therapeutic target for recovery from heart failure; 
these data have supported novel and exciting clini-
cal approaches aimed to target the SR directly (e.g. 
the gene therapy trials to increase the expression 
of SERCA in patients with heart failure [28]). The 
second important aspect is the discovery of an un-
loading-related phenomenon that we and others 
call “myocardial atrophy”, a set of dysfunctional 
features that make myocyte mass and function 
inadequate to sustain the workload of the heart 
when it is reloaded [29,30]. Clinical strategies that 
limit atrophy, such as partial unloading and other 
“smart” unloading modalities, various pharmaco-
logical therapies and even a specific gene therapy 
trial to over-express SERCA in LVAD patients (cli-
nicaltrials.gov NCT00534703) are currently being 
tested.
Another successful example of translational re-
search is the fast journey from the discovery of the 
pace maker current If in a physiology laboratory 
in the 1970s to recent large multi-centre clinical 
trials involving the HCN channel inhibitor ivabradine 
[31]. The first step of this process was to discover 
and link If with a class of cation channels, called 
hyperpolarization-activated, cyclic nucleotide gated 
(HCN) channels and which present predominantly 
in the SA node [32]. Subsequently, the relationship 
of HCN function with beta adrenergic regulation 
was described, but all this was still within the do-
main of basic physiology research. The translational 
part began when it was shown that pharmacologi-
cal inhibition of these channels reduces heart rate 
and it was hypothesized that this can be exploited 
clinically to reduce metabolic stress in the injured 
myocardium (the clinical starting point). Unlike beta 
adrenergic blockade, this approach does not hinder 
myocardial contractility and has limited effects out-
side a pure heart rate reducing (HRR) action [32]. 
Defining these properties and their clinical applica-
tions has been a constructive translational exercise 
which has led to the development of the HCN inhi-
bitor ivabradine followed by the BEAUTIFUL trial in 
more than 10,000 patients with ischemic heart di-
sease and LV systolic dysfunction[33] and the SHIfT 
trial in more than 6,000 heart failure patients [34]. 
Both trials showed that the rate of hospitalization 
is significantly reduced in patients with basal heart 
rate >70 bpm although overall mortality is not 
affected by this treatment. A recent clinical trial in 
>19,000 patients with stable coronary disease but 
without clinical heart failure (SIGNIFY) confirmed 
the observation that mortality is not affected by 
the addition of ivabradine to standard treatment, 
casting a shadow on its future use in clinical prac-
tice [35]. Overall, patients with LV dysfunction seem 
to benefit from treatment with ivabradine, possibly 
through an effect on LV remodeling [36]. This has 
triggered a series of basic research studies in two 
major areas: the first is the possibility that ivabradi-
ne exerts a beneficial effect in patients with heart 
failure where HCN channels are expressed in ventri-
cular myocytes and can contribute to the arrhyth-
mogenic substrate [37]. The other is the occurrence 
of HRR-independent effects, such as a reduction 
in myocardial fibrosis demonstrated in animal mo-
dels of heart failure and that open a new clinical 
application for this target (Figure 4) [38]. The latter 
observation feeds directly into clinical applications 
where anti-fibrotic therapy is taking central stage 
and now requires clinical validation and testing.
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Translational research in 
general is not a Phoenix
The examples reported here show how much over-
lap exists between basic, clinical and translational 
research in Cardiology, with even the direction of 
applicability (bedside-to-bench or bench-to-bedsi-
de) representing a matter of debate. The notion of 
an intricate relationship between clinical and fun-
damental aspects requires that limits and targets 
of translational research are defined. Two impor-
tant quantitative parameters should guide us. The 
first is time: there should be a tight temporal con-
nection between basic and clinical studies as part 
of a unitary effort; the two aspects should swiftly 
follow each other, possibly even be performed as 
a contemporary exercise. The second quantitative 
aspect is the impact of basic and clinical research 
on each other: there should be a real and significant 
clinical applicability following basic observations, 
which affects every-day clinical practice and opens 
new therapeutic targets. Vice versa clinical studies 
should open new fields of fundamental research 
that would not be otherwise performed and that 
significantly change the way we understand mecha-
nisms. Without a strong component in these two 
parameters, time and impact, the concept of trans-
lational research remains vague and its existence 
may even be questioned.
Figure 4.  Myocardial fibrosis, quantified using picrosirius red staining and expressed as collagen area frac-
tion, was measured in fixed sections of rat hearts with established heart failure (HF) 16 weeks 
after coronary artery ligation. One group of animals was treated with ivabradine (IVA) for 4 
weeks. Another group was treated with metoprolol for 4 weeks, to induce a similar 10-15% 
heart rate reduction (HRR). Sham-operated animals were used as control. Ivabradine induced 
a HRR-independent reduction of myocardial fibrosis. *** = p<0.001. Modified from [38].
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It was January 26, 1790 in Vienna that Mozart’s 
K 588 (Così fan tutte, ossia La scuola degli amanti: 
an Italian-language opera buffa in two acts) was 
first performed. The libretto was written by Loren-
zo Da Ponte who stated “È la fede delle femmine 
come l’Araba fenice: che vi sia ciascun lo dice, dove 
sia nessun lo sa!” He literally derived it from Pietro 
Metastasio, considered the most important writer 
of opera seria libretti, who created the famous dic-
to “Come l’araba Fenice, che vi sia ciascun lo dice, 
dove sia nessun lo sa” (from Demetrio, act II, sce-
ne III) meant to describe something uncomparable, 
impossibile to find, unique and/or difficult to catch 
(Figure 5). 
Figure 5.  Greek mythology reports the Phoenix as a 500 to 1400-year living bird that is cyclically rege-
nerated or reborn. His motto (post fata resurgo) well depicts the situation. He typically dies by 
fire and according to several classical Authors could symbolize renewal in general as well as the 
sun, time, the empire, metemspychosis, consecration, resurrection, life in the heavenly Paradise, 
Christ, Mary, virginity, the exceptional man, and certain aspects of Christian life. It is pictured 
in medieval art as endowed with a nimbus, which emphasizes the bird’s connection with the 
sun. There was no consensus about its coloration: some thought that the bird had a peacock-
like coloring and Herodotus’ claim of red and yellow is popular in many versions of the story 
on record. In terms of size the Phoenix was described similar to an eagle but others declared 
it was larger. A variety of cultures presents with analogues to the Phoenix: the Arabic Anga, 
the Hindu Garuda and Gandaberunda, the Russian Firebird, the Persian Simorgh, the Turkish 
Z´´umr´´ud´´u Anka, the Tibetan Me byi karmo, the Chinese Fenghuang and the Japanese H-ōo.
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Translational research in Cardiology should not 
be a Phoenix. As cardiovascular factors are pro-
portionately the most important ones and are 
heavily involved in overall survival [39], it is es-
sential that clinical questions formulated to solve 
a given problem or to add to the understanding 
of pathophysiological concepts or mechanisms for 
prevention, diagnosis or treatment are of impact 
and swiftly follow in time. In particular there should 
be a measurable impact and it should be shown 
that this adds as compared to previous factors or 
knowledge. For example ECG voltage criteria of LV 
hypertrophy (LVH) were shown to contribute to the 
prediction of sudden death in a residential cohort 
[40]. However, in a large cohort of black and white 
participants (all-comers) from the ARIC Study, they 
were associated with cardiovascular disease or co-
ronary (CVD/CHD) risk but did not significantly im-
prove CVD and CHD events risk prediction beyond 
the most used Framingham risk equations [41]. 
Therefore, the impact of ECG-LVH indexes might 
be comparatively minor or adding few to easier to 
obtain or less expensive risk factors. The long time 
needed [39,40] to reach these conclusions may ni-
cely show the difficulties of translational research 
when passing from a basic discipline such as epi-
demiology [5] to the clinical application in an all-
comers context. On the other hand, the promise 
of imaging modalities to unveil pathophysiological 
problems of LV function [2,7-10] might enable the 
detection of subtle abnormalities well in advance 
as compared to the natural evolution not driven 
by these much effective translational methods [42]. 
The missing thread could be that changes in LV 
geometry (concentric versus eccentric hypertrophy) 
are more important, for prognostic significance or 
predicting purposes [5,43], than ECG-LVH indexes 
[39,40] and thus specific imaging modalities [42] 
should be performed to better index anatomical 
correlates. Finally, LV function itself and its many re-
ceptor-, channels- and molecular-mediated interfe-
rences [22-31,38] will probably remain the Golden 
Fleece to look actively for, in order to detect with 
the highest probability an impacting significance in 
Translational Cardiology.
It is what we expect at the International Archives 
of Medicine. We hope to have on board of a no-
vel Argo boat a series of Heroes who will strive to 
connect basic and clinical Sciences bidirectionally, 
offering the evidence in an understandable way and 
transmitting to the Clinicians the essence of new 
impacting knowledge in plane terms and a timely 
fashion.
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